MYOS CORP Announces Significant New Patent for Increasing Mobility and Activity in Dogs
CEDAR KNOLLS, N.J., Dec. 12, 2023 /PRNewswire-PRWeb/ -- MYOS CORP, an innovation-driven medical nutrition company, announced today that it has been awarded US Patent No. 11,833,186, for its signature proprietary product, Fortetropin® - further cementing its science-backed claims to enhance mobility and activity in aging canines.
- CEDAR KNOLLS, N.J., Dec. 12, 2023 /PRNewswire-PRWeb/ -- MYOS CORP, an innovation-driven medical nutrition company, announced today that it has been awarded US Patent No.
- 11,833,186, for its signature proprietary product, Fortetropin® - further cementing its science-backed claims to enhance mobility and activity in aging canines.
- "We're gratified that the US Patent Office continues to recognize the distinctiveness and effectiveness of Fortetropin, granting us robust patent protection."
- "MYOS stands out in protecting our innovative products with patents backed by clinically-validated, peer-reviewed studies," said MYOS CORP CEO Joe Mannello.